CD39 is expressed by a wide range of cutaneous T-cell lymphomas.
Journal
Skin health and disease
ISSN: 2690-442X
Titre abrégé: Skin Health Dis
Pays: England
ID NLM: 9918227353706676
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
5
4
2024
Statut:
epublish
Résumé
CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.
Identifiants
pubmed: 38577051
doi: 10.1002/ski2.334
pii: SKI2334
pmc: PMC10988668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e334Informations de copyright
© 2024 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.